Actively Recruiting
Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA
Led by Queen Mary University of London · Updated on 2026-02-23
122
Participants Needed
6
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of WAVE is to test the hypothesis that thermal ablation (microwave or RFA) is non-inferior to surgery in the biochemical (and if so, in the clinical) cure of unilateral PA, according to the international consensus PASO criteria. Secondary objectives are to determine whether either intervention is superior to the other in relation to the following outcomes. Where no superiority of either intervention is established, non-inferiority of thermal ablation against adrenalectomy will be sought. * Frequency and severity of adverse events * Length of inpatient stay * Patient satisfaction * Quality of life * Return to activities of daily living An additional secondary objective in the thermal ablation group alone will be anatomical efficacy of ablation.
CONDITIONS
Official Title
Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Primary aldosteronism diagnosed according to international guidelines
- Unilateral disease confirmed by adrenal venous sampling or PET-CT
- Presence of ipsilateral benign adrenal abnormality suitable for both thermal ablation and surgery
- Able and willing to give informed consent
- Randomisation approved by multidisciplinary team
You will not qualify if you...
- Absolute contraindication to alpha- or beta-adrenoceptor antagonist therapy or CT contrast
- Contraindication or unwillingness for either surgery or thermal ablation
- Inability to stop beta-adrenoceptor antagonist therapy for 2 weeks
- Unwilling to undergo laparoscopic adrenalectomy or thermal ablation
- Unwilling to comply with study visit schedule
- Pregnancy or unwillingness to use secure contraception during the study (for female participants)
- Life-limiting comorbidity as judged by the principal investigator
- Evidence of autonomous cortisol secretion requiring adrenalectomy independent of aldosterone secretion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Cambridge University Hospitals NHS Foundation Trust
Cambridge, SMLG, United Kingdom, CB2 0QQ
Actively Recruiting
2
St Bartholomew's Hospital
London, United Kingdom, EC1A 7BE
Actively Recruiting
3
University College London Hospital NHS Foundation Trust
London, United Kingdom, NW1 2PG
Actively Recruiting
4
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom, SE1 9RT
Actively Recruiting
5
Imperial College Healthcare NHS Trust
London, United Kingdom, W12 0HS
Actively Recruiting
6
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom, S10 2JF
Actively Recruiting
Research Team
A
Aklima Khatun
CONTACT
T
Tumi Kaminsas
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here